China is now the second-largest national market of pharmaceuticals in the world, and shows the strong growth trend at least in the next ten years since China government has determined the Healthy China 2030 policy makes it as the core policy. There’s never been a better time for the multinational pharma companies to invest drug business in China. Accestra continuously focuses on the ever-changing pharmaceutical environment in China, and has great resource of local drug firms and sales channels. We sincerely hope to cooperate with foreign companies to introduce good pharmaceutical products into China and develop the local market.
Production technology transfer of innovative drugs and generic drugs to China local pharmaceutical company;
Sales agent of business in China.